Skip to main content

Market Overview

B Riley Likes Tocagen On Prospects For Company's Brain Cancer Drug

B Riley Likes Tocagen On Prospects For Company's Brain Cancer Drug

A little more than a year after its initial public offering, Tocagen Inc (NASDAQ: TOCA) has traded down 26 percent, but experts are decidedly bullish on the company’s prospects and potential valuation.

The Rating

B Riley analyst Madhu Kumar initiated coverage on Tocagen with a Buy rating and a $15 price target.

The Thesis

As Kumar sees it, Toca 511/FC has potential to transform the treatment of recurrent high-grade glioma (RHGG), a brain cancer affecting about 14,000 per year with limited-efficacy treatment options.

“Overall, RHGG remains a key clinical opportunity for novel therapies that can demonstrate improved therapeutic response,” Kumar wrote in a Wednesday note.

The failures of comparable candidates for RHGG, such as Vascular Biogenics Ltd (NASDAQ: VBLT)’s VB-111, have little read-across to Toca 511/FC, he said.

Given that Phase 1 data demonstrated positive enough results to merit Breakthrough Therapy Designation and PRIME Designation, Kumar anticipates success in Tocagen’s ongoing Phase 3 TOCA 5 trial.

Interim readouts due in the second half of 2018 and first half of 2019 are seen to propel the stock, with the latter milestone driving a key inflection point. The analyst assumes a 30-percent probability of launch with a 30-percent market share but notes improvements to the estimates could support a $90 share price.

Price Action

Tocagen shares traded up 3 percent to $9.74 at time of publication.

Related Links:

Ziopharm Oncology CEO Wants To Disrupt The CAR-T Supply Chain

DelMar Pharma CEO Sheds Light On Glioblastoma, And How Its Drug Could Help John McCain

Latest Ratings for TOCA

Sep 2019CitiDowngradesBuyNeutral
Sep 2019Chardan CapitalDowngradesBuyNeutral
Sep 2019Evercore ISI GroupDowngradesOutperformIn-Line

View More Analyst Ratings for TOCA
View the Latest Analyst Ratings


Related Articles (TOCA)

View Comments and Join the Discussion!

Posted-In: B Riley Madhu KumarAnalyst Color Price Target Initiation Analyst Ratings Best of Benzinga

Latest Ratings

SCYXAegis CapitalMaintains40.0
ARGOBoenning & ScattergoodDowngrades
TLSAZacks Investment ResearchInitiates Coverage On7.5
TOTJP MorganUpgrades
WSOMorgan StanleyMaintains244.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at